Kyrgios Ioannis, Giza Styliani, Kotanidou Eleni P, Kleisarchaki Angeliki, Tsinopoulou Vasiliki Rengina, Papadopoulou Anastasia, Markantonatou Anthi-Marina, Kanellidou Eleni, Giannakou Anastasia, Galli-Tsinopoulou Assimina
4th Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Immunology, Papageorgiou General Hospital, Thessaloniki, Greece.
J Clin Pharm Ther. 2019 Feb;44(1):102-108. doi: 10.1111/jcpt.12765. Epub 2018 Oct 10.
Although a beneficial effect of selenium (Se) administration has been proposed in adults with autoimmune thyroiditis (AT), there is a paucity of similar data in children and adolescents. The purpose of the study was to investigate whether administration of a high dose of organic Se (200 μg daily as l-selenomethionine) has an effect on antithyroid antibody titres in children and adolescents with AT.
Seventy-one (71) children and adolescents, with a mean age of 11.3 ± 0.3 years (range 4.5-17.8), diagnosed with AT (antibodies against thyroid peroxidase [anti-TPO] and/or thyroglobulin [anti-Tg] ≥60 IU/mL, euthyroidism or treated hypothyroidism and goitre in thyroid gland ultrasonography) were randomized to receive 200 μg l-selenomethionine or placebo daily for 6 months. Blood samples were drawn for measurement of serum fT4, TSH, anti-TPO and anti-Tg levels, and thyroid gland ultrasonography was performed at the entry to the study and after 6 months of treatment.
At the end of the study, a statistically significantly higher reduction in anti-Tg levels was observed in the Se group compared to the placebo group (Δ: -70.9 ± 22.1 vs -6.7 ± 60.6 IU/mL, P = 0.021). Although anti-TPO levels were also decreased in the Se group, this change was not statistically different from that of the control group (Δ: -116.2 ± 68.4 vs +262.8 ± 255.5 IU/mL, P = 0.219). No significant difference in thyroid gland volume was observed between the two study groups (P > 0.05).
In this original study, organic Se supplementation appears to reduce anti-Tg levels in children and adolescents with AT.
尽管已提出补充硒（Se）对自身免疫性甲状腺炎（AT）成年患者有益，但儿童和青少年中类似的数据较少。本研究的目的是调查高剂量有机硒（每天200μg的L-硒代蛋氨酸）对患有AT的儿童和青少年抗甲状腺抗体滴度是否有影响。
71名平均年龄为11.3±0.3岁（范围4.5 - 17.8岁）、被诊断为AT（抗甲状腺过氧化物酶[抗-TPO]和/或甲状腺球蛋白[抗-Tg]抗体≥60IU/mL，甲状腺功能正常或经治疗的甲状腺功能减退，且甲状腺超声检查有甲状腺肿）的儿童和青少年被随机分为两组，分别每天接受200μg的L-硒代蛋氨酸或安慰剂，持续6个月。在研究开始时和治疗6个月后采集血样，测定血清游离甲状腺素（fT4）、促甲状腺激素（TSH）、抗-TPO和抗-Tg水平，并进行甲状腺超声检查。
研究结束时，与安慰剂组相比，硒组抗-Tg水平的降低在统计学上有显著差异（差值：-70.9±22.1 vs -6.7±60.6IU/mL，P = 0.021）。虽然硒组抗-TPO水平也有所下降，但与对照组相比，这种变化在统计学上无显著差异（差值：-116.2±68.4 vs +262.8±255.5IU/mL，P = 0.219）。两个研究组之间甲状腺体积无显著差异（P>0.05）。
在这项原创研究中，补充有机硒似乎可降低患有AT的儿童和青少年的抗-Tg水平。
